Juan Antonio López-Villodres

Prof. Juan Antonio López-Villodres

Universidad de Málaga, Facultad de Medicina
avatar
Co-authors
avatar
Following
avatar
Followers

Research Focus & Metrics

Explore full metrics on Scilit

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
ABAna Bermúdez
Ana Bermúdez
IAIsabel Arranz-Salas
Isabel Arranz-Salas
SMSilvia Mercado-Sáenz
Silvia Mercado-Sáenz
JLJuan Antonio López-Villodres
Juan Antonio López-Villodres
VGVirginia González
Virginia González
DFDiego Teófilo Bermúdez Flores
Diego Teófilo Bermúdez Flores
Gastric cancer (GC) is one of the leading causes of cancer-related death. The combination of new molecular classifications with clinicopathological data could contribute to the individualization of patients and to the development of new therapeutic strategies. We examined the various associations in two molecular types of GC: HER2-positive (human epidermal growth factor receptor 2) and microsatellite instability (MSI), assessing their influence on treatment and prognosis. A retrospective study of 142 GC patients was performed with molecular characterization through HER2 overexpression and DNA repair protein expression for MSI. The percentage of HER2-positive tumors was 13.4%, predominantly in men. Correlations were found with intestinal type, metastases, advanced stages and chemotherapy. Almost 75% of HER2-positive patients died. MSI occurred in 16.2%, associated with advanced age, female sex, distal location and intestinal type. These patients had few metastases and low stages. The percentage of deaths was higher among MSI patients who received perioperative chemotherapy. The determination of HER2 and MSI status in GC is important for their association with specific clinicopathological features and for their prognostic and predictive value.
8 November 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
MRMaría Dolores Rodriguez-Pérez
María Dolores Rodriguez-Pérez
JLJuan Antonio López-Villodres
Juan Antonio López-Villodres
MRMARÍA MONSALUD ARREBOLA RAMÍREZ
MARÍA MONSALUD ARREBOLA RAMÍREZ
EAEsther Martin Aurioles
Esther Martin Aurioles
MPMARIA AFRICA FERNANDEZ PRIOR
MARIA AFRICA FERNANDEZ PRIOR
JGJose Antonio Gonzalez-Correa
Jose Antonio Gonzalez-Correa
The aim of this study was to determine whether hydroxytyrosol administration prevented kidney damage in an experimental model of type 1 diabetes mellitus in rats. Hydroxytyrosol was administered to streptozotocin-diabetic rats: 1 and 5 mg/kg/day p.o. for two months. After hydroxytyrosol administration, proteinuria was significantly reduced (67–73%), calculated creatinine clearance was significantly increased (26–38%), and the glomerular volume and glomerulosclerosis index were decreased (20–30%). Hydroxytyrosol reduced oxidative and nitrosative stress variables and thromboxane metabolite production. Statistical correlations were found between biochemical and kidney function variables. Oral administration of 1 and 5 mg/kg/day of hydroxytyrosol produced an antioxidant and nephroprotective effect in an experimental model of type 1-like diabetes mellitus. The nephroprotective effect was significantly associated with the systemic and renal antioxidant action of hydroxytyrosol, which also influenced eicosanoid production.
1 April 2012 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JLJuan Antonio López-Villodres
Juan Antonio López-Villodres
JCJose pedro de la cruz
Jose pedro de la cruz
JMJavier Muñoz-Marin
Javier Muñoz-Marin
AGAna Guerrero
Ana Guerrero
JRJosé Julio Reyes
José Julio Reyes
JGJose Antonio Gonzalez-Correa
Jose Antonio Gonzalez-Correa
27 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
JLJuan Antonio López-Villodres
Juan Antonio López-Villodres
Alejandro Escamilla-SánchezAlejandro Escamilla-Sánchez
Alejandro Escamilla-Sánchez
SMSilvia Mercado-Sáenz
Silvia Mercado-Sáenz
CACarmen Alba
Carmen Alba
LRLuis Manuel Rodriguez-Perez
Luis Manuel Rodriguez-Perez
DFDiego Teófilo Bermúdez Flores
Diego Teófilo Bermúdez Flores
In the last decade, the role of the microbiota–gut–brain axis has been gaining momentum in the context of many neurodegenerative and metabolic disorders, including Alzheimer’s disease (AD) and diabetes, respectively. Notably, a balanced gut microbiota contributes to the epithelial intestinal barrier maintenance, modulates the host immune system, and releases neurotransmitters and/or neuroprotective short-chain fatty acids. However, dysbiosis may provoke immune dysregulation, impacting neuroinflammation through peripheral–central immune communication. Moreover, lipopolysaccharide or detrimental microbial end-products can cross the blood–brain barrier and induce or at least potentiate the neuropathological progression of AD. Thus, after repeated failure to find a cure for this dementia, a necessary paradigmatic shift towards considering AD as a systemic disorder has occurred. Here, we present an overview of the use of germ-free and/or transgenic animal models as valid tools to unravel the connection between dysbiosis, metabolic diseases, and AD, and to investigate novel therapeutical targets. Given the high impact of dietary habits, not only on the microbiota but also on other well-established AD risk factors such as diabetes or obesity, consistent changes of lifestyle along with microbiome-based therapies should be considered as complementary approaches.